Mark A. Marzinke

10.4k total citations
171 papers, 3.1k citations indexed

About

Mark A. Marzinke is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Mark A. Marzinke has authored 171 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Infectious Diseases, 74 papers in Virology and 53 papers in Epidemiology. Recurrent topics in Mark A. Marzinke's work include HIV/AIDS Research and Interventions (110 papers), HIV Research and Treatment (74 papers) and HIV/AIDS drug development and treatment (59 papers). Mark A. Marzinke is often cited by papers focused on HIV/AIDS Research and Interventions (110 papers), HIV Research and Treatment (74 papers) and HIV/AIDS drug development and treatment (59 papers). Mark A. Marzinke collaborates with scholars based in United States, South Africa and Uganda. Mark A. Marzinke's co-authors include Craig W. Hendrix, Teresa L. Parsons, William Clarke, Margaret Clagett‐Dame, Peter L. Anderson, Charlene S. Dezzutti, Jared M. Baeten, Sharon L. Hillier, Susan H. Eshleman and Manjula Gunawardana and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Mark A. Marzinke

164 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark A. Marzinke United States	30	2.1k	1.1k	972	480	354	171	3.1k
Sheldon Morris United States	33	1.3k 0.6×	1.2k 1.1×	802 0.8×	348 0.7×	456 1.3×	102	2.8k
Patricia Reichelderfer United States	27	2.1k 1.0×	972 0.9×	1.9k 2.0×	286 0.6×	511 1.4×	56	3.4k
Philip Cunningham Australia	35	1.6k 0.7×	1.5k 1.4×	1.2k 1.3×	175 0.4×	291 0.8×	113	3.5k
John R. Dyer Australia	27	1.4k 0.7×	719 0.7×	794 0.8×	332 0.7×	459 1.3×	111	3.3k
Francesca Little South Africa	33	1.2k 0.6×	898 0.8×	465 0.5×	345 0.7×	315 0.9×	100	3.1k
Conrad Muzoora Uganda	29	2.4k 1.1×	1.8k 1.7×	474 0.5×	725 1.5×	127 0.4×	103	3.3k
Stanley Read Canada	37	1.5k 0.7×	1.1k 1.1×	749 0.8×	469 1.0×	85 0.2×	142	3.4k
Edward J. Fuchs United States	26	1.1k 0.5×	525 0.5×	703 0.7×	146 0.3×	317 0.9×	70	2.3k
Lisa C. Rohan United States	37	1.5k 0.7×	804 0.7×	1.1k 1.1×	322 0.7×	1.3k 3.6×	135	4.0k
Anita Rachlis Canada	31	2.6k 1.2×	1.6k 1.5×	1.6k 1.6×	280 0.6×	107 0.3×	135	4.1k

Countries citing papers authored by Mark A. Marzinke

Since Specialization

Citations

This map shows the geographic impact of Mark A. Marzinke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Marzinke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Marzinke more than expected).

Fields of papers citing papers by Mark A. Marzinke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Marzinke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Marzinke. The network helps show where Mark A. Marzinke may publish in the future.

Co-authorship network of co-authors of Mark A. Marzinke

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Marzinke. A scholar is included among the top collaborators of Mark A. Marzinke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Marzinke. Mark A. Marzinke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rutstein, Sarah E., Jane S. Chen, Yaw Agyei, et al.. (2025). Improving HIV Prevention Among Heterosexual Men Seeking Sexually Transmitted Infection Services in Malawi: Protocol for a Type I Effectiveness-Implementation Hybrid Randomized Controlled Trial of Systems Navigator–Delivered Integrated Prevention Package (HPTN 112-NJIRA Study). JMIR Research Protocols. 14. e72981–e72981.

Anderson, Peter L., et al.. (2025). Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 100(2). 162–169.

Liu, Albert, Holly Gundacker, Barbra A. Richardson, et al.. (2024). Phase 1 randomized pharmacokinetic and safety study of a 90‐day tenofovir vaginal ring in the United States. Journal of the International AIDS Society. 27(3). e26223–e26223. 1 indexed citations

Parsons, Teresa L., et al.. (2023). Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. Journal of Pharmaceutical and Biomedical Analysis. 228. 115307–115307. 6 indexed citations

Anderson, Peter L., Mark A. Marzinke, & David V. Glidden. (2023). Updating the Adherence–Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women. Clinical Infectious Diseases. 76(10). 1850–1853. 17 indexed citations

Heijden, Yuri van der, Matthew S. Shotwell, Violet Chihota, et al.. (2023). High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy. 67(2). e0129722–e0129722. 2 indexed citations

Nowak, Rebecca G., Mark A. Marzinke, Daniel J. Morgan, et al.. (2023). Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria. PLoS ONE. 18(3). e0282999–e0282999. 4 indexed citations

Matthews, Lynn T., Esther C. Atukunda, Christina Psaros, et al.. (2023). High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study. PLoS Medicine. 20(2). e1004088–e1004088. 16 indexed citations

Xiao, Peng, Sanjeev Gumber, Mark A. Marzinke, et al.. (2022). Hypo-osmolar rectal douche tenofovir formulation prevents simian/human immunodeficiency virus acquisition in macaques. JCI Insight. 7(23). 1 indexed citations

10.

Brown, Todd T., Krista Yuhas, Kenneth H. Mayer, et al.. (2021). Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. Journal of Antimicrobial Chemotherapy. 77(2). 500–506. 4 indexed citations

11.

Liu, Albert, Holly Gundacker, Blažej Neradilek, et al.. (2021). Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States. Journal of the International AIDS Society. 24(6). e25747–e25747. 17 indexed citations

12.

Trani, Nicola Di, Fernanda P. Pons‐Faudoa, Antons Sizovs, et al.. (2021). Extending Drug Release from Implants via Transcutaneous Refilling with Solid Therapeutics. Advanced Therapeutics. 5(2). 17 indexed citations

13.

McGowan, Ian, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M. Brand, et al.. (2021). An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses. 38(4). 279–287. 9 indexed citations

14.

Jarrell, Andrew, Rachel Kruer, M. Veronica Dioverti, et al.. (2020). Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. Clinical Infectious Diseases. 73(1). 101–106. 10 indexed citations

15.

Pons‐Faudoa, Fernanda P., Nicola Di Trani, Antons Sizovs, et al.. (2020). Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics. 12(10). 981–981. 99 indexed citations

16.

Fogel, Jessica M., Noya Galai, William Clarke, et al.. (2020). Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic. PLoS ONE. 15(10). e0240890–e0240890. 5 indexed citations

17.

Brown, Elizabeth R., Craig W. Hendrix, Ariane van der Straten, et al.. (2020). Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial. Journal of the International AIDS Society. 23(11). e25634–e25634. 50 indexed citations

18.

Veazey, Ronald S., Mark A. Marzinke, Lakmini Widanapathirana, et al.. (2019). A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques. Antimicrobial Agents and Chemotherapy. 64(3). 52 indexed citations

19.

Lund, Jennifer M., Kristina Broliden, Maria Pyra, et al.. (2016). HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. Journal of Virology. 90(21). 9855–9861. 7 indexed citations

20.

Petrides, Athena K., et al.. (2014). Application and Utility of Pharmacogenetics in the Clinical Laboratory. 1(1). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact